Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

 131.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 137.50
  • 52 Week Low: 100.50
  • Currency: UK Pounds
  • Shares Issued: 106.23m
  • Volume: 818
  • Market Cap: £139.16m
  • RiskGrade: 54

Cello Health sells Pulsar business to Access Intelligence

By Michele Maatouk

Date: Wednesday 02 Oct 2019

LONDON (ShareCast) - (Sharecast News) - Healthcare-focused advisory group Cello Health has sold its social media analytics software business, Pulsar, to Access Intelligence for £4.5m in shares.
The AIM-listed company said on Wednesday that the disposal will allow it to focus its capital investment on the higher growth and higher margin healthcare business as well as supporting the development of the core Signal business.

The consideration will be satisfied through the issue of just over 8.6m ordinary shares of 5 pence each and a £1 cash payment. Following the acquisition, Cello will own around 11.3% of Access Intelligence.

Cello chief executive Mark Scott said: "We are delighted that Pulsar can now begin the next stage in its development as a business whilst enabling Cello to focus on its core healthcare activities. We look forward to the ongoing partnership with Access Intelligence, both as a shareholder and as an ongoing user of Pulsar."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Cello Health Market Data

Currency UK Pounds
Share Price 131.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 137.50
52 Week Low 100.50
Volume 818
Shares Issued 106.23m
Market Cap £139.16m
RiskGrade 54

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
61.75% below the market average61.75% below the market average61.75% below the market average61.75% below the market average61.75% below the market average
82.86% above the sector average82.86% above the sector average82.86% above the sector average82.86% above the sector average82.86% above the sector average
Price Trend
42.83% above the market average42.83% above the market average42.83% above the market average42.83% above the market average42.83% above the market average
33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average
Income
9.38% above the market average9.38% above the market average9.38% above the market average9.38% above the market average9.38% above the market average
46.67% above the sector average46.67% above the sector average46.67% above the sector average46.67% above the sector average46.67% above the sector average
Growth
32.09% below the market average32.09% below the market average32.09% below the market average32.09% below the market average32.09% below the market average
41.18% below the sector average41.18% below the sector average41.18% below the sector average41.18% below the sector average41.18% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 2
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  Interim Final
Ex-Div 03-Oct-19 25-Apr-19
Paid 01-Nov-19 24-May-19
Amount 1.15p 2.75p

Trades for 06-Dec-2019

Time Volume / Share Price
15:08 785 @ 130.50p
14:08 15 @ 130.50p
14:07 18 @ 130.50p

Cello Health Key Personnel

CEO Mark Scott

Top of Page